错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma

  • Julia Paczkowska,
  • Ming Tang,
  • Kyle T. Wright,
  • Li Song,
  • Kelsey Luu,
  • Vignesh Shanmugam,
  • Emma L. Welsh,
  • Jason L. Weirather,
  • Naomi Besson,
  • Harrison Olszewski,
  • Billie A. Porter,
  • Kathleen L. Pfaff,
  • Robert A. Redd,
  • Fathima Zumla Cader,
  • Elisa Mandato,
  • Jing Ouyang,
  • Eleonora Calabretta,
  • Gali Bai,
  • Lee N. Lawton,
  • Philippe Armand,
  • Scott J. Rodig,
  • Xiaole Shirley Liu,
  • Margaret A. Shipp

摘要

Hodgkin Reed-Sternberg (HRS) cells of classic Hodgkin lymphoma (cHL), like many solid tumors, elicit ineffective immune responses. However, patients with cHL are highly responsive to PD-1 blockade, which largely depends on HRS cell-specific retention of MHC class II and implicates CD4+ T cells and additional MHC class I-independent immune effectors. Here, we utilize single-cell RNA sequencing and spatial analysis to define shared circulating and microenvironmental features of the immune response to PD-1 blockade in cHL. Compared with non-responders, responding patients have more circulating CD4+ naïve and central memory T cells and B cells, as well as more diverse CD4+ T cell and B cell receptor repertoires. Importantly, a population of circulating and tumor-infiltrating IL1β+ monocytes/macrophages is detectable in patients with cHL but not healthy donors, and a proinflammatory, tumor-promoting signature of these circulating IL1β+ monocytes is associated with resistance to PD-1 blockade in cHL. Altogether, our findings reveal extensive immune rewiring and complementary roles of CD4+ T cells, B cells and IL1β+ monocytes in the response to PD-1 blockade and suggest that these features can be captured with a peripheral blood test.